Fragmented Trading in US Niche Stocks Driven by AI and Diagnostic CatalystsGlobal Report·22 hours agoVCYT-2.19%YJ-6.99%
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesdaybenzinga_article·Jul 15 at 05:59 AMTNGX-2.99%FISN-3.84%
SPCX, AMD, XE – Cathie Wood Bets Millions on SpaceX and XE, Sells AMD AgainTip Ranks·Jul 8 at 08:24 AMXE-8.54%LLY+0.86%
Is Veracyte (VCYT) Fully Valued As Insider Selling And Index Additions Draw Attention?Simplywall·Jul 7 at 10:59 PMVCYT-2.19%
Veracyte director Karin Eastham disposes of 3,729 common shares worth $197,478.18PUBT·Jun 22 at 03:31 PMVCYT-2.19%
As AbbVie eyes Apogee, these biotech stocks earn the highest quant ratingsMSN·Jun 22 at 08:55 AMNTLA-3.33%LEGN-5.57%
Veracyte (VCYT) Stock Could Be 4.5% Overvalued After Its Recent RunSimplywall·Jun 18 at 09:59 PMVCYT-2.19%
Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stockbenzinga_article·Jun 10 at 09:43 PMCERS+2.09%PACB-2.86%
Veracyte (NASDAQ:VCYT) Now Covered by Analysts at Wolfe ResearchMarket Beat·Jun 2 at 09:04 AMVCYT-2.19%
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S. | VCYT Stock NewsStockTitan·May 31 at 10:30 PMVCYT-2.19%
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer | VCYT Stock NewsStockTitan·May 29 at 11:00 PMVCYT-2.19%
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy | VCYT Stock NewsStockTitan·May 29 at 06:15 AMVCYT-2.19%
